Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a “Painless” Lead Investigational Candidate for Therapeutic Applications
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nerve Growth Factor (NGF) holds a great therapeutic promise for Alzheimer's disease, diabetic neuropathies, ophthalmic diseases, dermatological ulcers. However, the necessity for systemic delivery has hampered the clinical applications of NGF due to its potent pro-nociceptive action. A "painless" human NGF (hNGF R100E) mutant has been engineered. It has equal neurotrophic potency to hNGF but a lower nociceptive activity. We previously described and characterized the neurotrophic and nociceptive properties also of the hNGF P61S and P61SR100E mutants, selectively detectable against wild type hNGF. However, the reduced pain-sensitizing potency of the "painless" hNGF mutants has not been quantified. OBJECTIVES AND RESULTS: Aiming at the therapeutic application of the "painless" hNGF mutants, we report on the comparative functional characterization of the precursor and mature forms of the mutants hNGF R100E and hNGF P61SR100E as therapeutic candidates, also in comparison to wild type hNGF and to hNGF P61S. The mutants were assessed by a number of biochemical, biophysical methods and assayed by cellular assays. Moreover, a highly sensitive ELISA for the detection of the P61S-tagged mutants in biological samples has been developed. Finally, we explored the pro-nociceptive effects elicited by hNGF mutants in vivo, demonstrating an expanded therapeutic window with a ten-fold increase in potency. CONCLUSIONS: This structure-activity relationship study has led to validate the concept of developing painless NGF as a therapeutic, targeting the NGF receptor system and supporting the choice of hNGF P61S R100E as the best candidate to advance in clinical development. Moreover, this study contributes to the identification of the molecular determinants modulating the properties of the hNGF "painless" mutants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
Monera, O. D., Kay, C. M., & Hodges, R. S. (1994) · Protein Science · doi:10.1002/pro.5560031110 · Cited by 351 · cited 1×
“This behaviour was reported for model proteins designed with intra- and intermolecular predominating electrostatic repulsive rather than attractive interactions [43].”
BackgroundNeurotrophins and neuronal differentiation in the central nervous system
McAllister, A. K. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000920 · Cited by 175
Cited by
Lipid Nanoparticle Delivery of Chemically Modified NGF R100W mRNA Alleviates Peripheral Neuropathy
Yu, X., Yang, Z., Zhang, Y., Xia, J., Zhang, J., Han, Q., Yu, H., Wu, C., Xu, Y., Xu, W., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202127 · Cited by 38
Baldassarro, V. A., Cescatti, M., Rocco, M. L., Aloe, L., Lorenzini, L., Giardino, L., & Calzà, L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1111170 · Cited by 26
Rivera, K. O., Cuylear, D. L., Duke, V. R., O’Hara, K. M., Zhong, J. X., Elghazali, N. A., Finbloom, J. A., Kharbikar, B. N., Kryger, A. N., Miclau, T., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1190371 · Cited by 22
Metadata
- Authors
- Malerba, F., Paoletti, F., Bruni Ercole, B., Materazzi, S., Nassini, R., Coppi, E., Patacchini, R., Capsoni, S., Lamba, D., & Cattaneo, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-09-15
- Volume
- 10
- Issue
- 9
- Pages
- e0136425
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2207920502
- Cited by
- 44
- References
- 3
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.